Jacobs Levy Equity Management, Inc Concert Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $985,745 - $1.55 Million	-366,448 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.15 $91,968 - $120,399	29,012 Added 8.6%	366,448 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$3.77 - $5.24 $838,840 - $1.17 Million	222,504 Added 193.6%	337,436 $1.42 Million
Q1 2021 May 17, 2021	SELL	$4.86 - $13.07 $393,018 - $1.06 Million	-80,868 Reduced 41.3%	114,932 $574,000
Q4 2020 Feb 16, 2021	SELL	$9.48 - $12.84 $15,490 - $20,980	-1,634 Reduced 0.83%	195,800 $2.48 Million
Q3 2020 Nov 16, 2020	SELL	$8.67 - $10.82 $293,271 - $365,997	-33,826 Reduced 14.63%	197,434 $1.94 Million
Q2 2020 Aug 17, 2020	SELL	$7.8 - $11.52 $69,786 - $103,069	-8,947 Reduced 3.72%	231,260 $2.3 Million
Q1 2020 May 15, 2020	BUY	$5.98 - $13.09 $139,304 - $304,931	23,295 Added 10.74%	240,207 $2.12 Million
Q4 2019 Feb 14, 2020	BUY	$5.71 - $9.22 $745,794 - $1.2 Million	130,612 Added 151.35%	216,912 $2 Million
Q3 2019 Nov 14, 2019	BUY	$5.88 - $12.35 $276,360 - $580,450	47,000 Added 119.59%	86,300 $507,000
Q2 2019 Aug 13, 2019	BUY	$9.44 - $13.12 $370,992 - $515,615	39,300 New	39,300 $472,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.